Zealand Pharma A/S (ZEAL): Price and Financial Metrics
ZEAL Stock Summary
- Of note is the ratio of Zealand Pharma A's sales and general administrative expense to its total operating expenses; only 0.27% of US stocks have a lower such ratio.
- The ratio of debt to operating expenses for Zealand Pharma A is higher than it is for about only 0.3% of US stocks.
- With a year-over-year growth in debt of -100%, Zealand Pharma A's debt growth rate surpasses merely 0% of about US stocks.
- Stocks that are quantitatively similar to ZEAL, based on their financial statements, market capitalization, and price volatility, are HTLD, CPG, GTE, PTVCB, and SD.
- Visit ZEAL's SEC page to see the company's official filings. To visit the company's web site, go to www.zealandpharma.com.
ZEAL Stock Price Chart Interactive Chart >
ZEAL Price/Volume Stats
| Current price | $33.09 | 52-week high | $44.42 |
| Prev. close | $31.74 | 52-week low | $29.43 |
| Day low | $32.03 | Volume | 1,100 |
| Day high | $33.09 | Avg. volume | 13,609 |
| 50-day MA | $32.15 | Dividend yield | N/A |
| 200-day MA | $35.57 | Market Cap | 1.44B |
Zealand Pharma A/S (ZEAL) Company Bio
Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company was founded in 1997 and is based in Copenhagen, Denmark.
Latest ZEAL News From Around the Web
Below are the latest news stories about Zealand Pharma A that investors may wish to consider to help them evaluate ZEAL as an investment opportunity.
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and ObesityCompany announcement – No. 21/ 2021 Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity New studies mark an important advancement of Boehringer Ingelheim’s cardiometabolic focus areas obesity and NASH.The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on both chronic weight management and NASH improvement.The Phase 2 trials for BI 456906 in obesity and NASH are part of the long-term collaboration between Boehringer Ingelheim and Zealand Pharma, with a prior Phase 2 trial of BI 456906 in people with type 2 diabetes initiated in 2020. Ingelheim, Germany and Copenhagen, Denmark, 13 April, 2021 – Boehringer Ingelheim and Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) announced the initiation of two Phase 2 trials of the GLP-1/gl... |
With a New Diabetes Product Coming to Market, What Lies Ahead for Zealand Pharma Investors?A new, easier-to-administer treatment for severe hypoglycemia has observers and investors wondering where its creators will go next. |
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCompany announcement – No. 20/ 2021 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, April 9, 2021 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached files. # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on ... |
Zealand Pharma increases its share capital as a consequence of exercise of employee warrantsCompany announcement – No. 19/ 2021 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, DK and Boston, MA, April 9, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 21,650 divided into 21,650 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma-share at a p... |
Total number of shares and voting rights in Zealand Pharma at March 31, 2021Company announcement – No. 18/ 2021 Total number of shares and voting rights in Zealand Pharma at March 31, 2021 Copenhagen, DK and Boston, MA, U.S., March 31, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. In Company announcement No. 14/2021 from March 19, 2021, Zealand announced an increase in share capital relating to the exercise of employee warrants. Following this announcement, the table below lists the total n... |
ZEAL Price Returns
| 1-mo | 6.36% |
| 3-mo | -11.01% |
| 6-mo | -11.12% |
| 1-year | -5.08% |
| 3-year | 120.60% |
| 5-year | N/A |
| YTD | -7.93% |
| 2020 | 8.25% |
| 2019 | 185.96% |
| 2018 | -14.63% |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching ZEAL
Want to do more research on Zealand Pharma A's stock and its price? Try the links below:Zealand Pharma A (ZEAL) Stock Price | Nasdaq
Zealand Pharma A (ZEAL) Stock Quote, History and News - Yahoo Finance
Zealand Pharma A (ZEAL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...